Personalized mRNA cancer vaccine cuts melanoma recurrence risk by 42% in landmark phase 3 trial

A personalized mRNA cancer vaccine has cleared its biggest hurdle yet. Results from the phase 3 INTerpath-001 trial, presented at the 2026 ESMO Congress in Madrid, showed that adding intismeran autogene (Moderna/Merck) to adjuvant pembrolizumab significantly improved outcomes in patients with completely resected high-risk (stage IIB–IV) melanoma. The combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38%, compared to pembrolizumab alone — marking the first phase 3 success for a personalized cancer vaccine.

Intismeran works by encoding up to 34 patient-specific tumor neoantigens into an mRNA construct, stimulating T-cell responses tailored to each individual's cancer. The vaccine takes 6–8 weeks to manufacture per patient and is administered alongside the PD-1 inhibitor pembrolizumab. Notably, the survival benefit emerged after the first 6 months — consistent with the vaccine's mechanism and delayed administration — with the recurrence risk dropping by 58% beyond that window. Overall survival data remain immature. Full results are slated for publication in The New England Journal of Medicine.

By the Numbers:

• 42% reduction in risk of recurrence or death (HR, 0.58; P < .001)
• 2-year RFS: 82.2% (combination) vs. 70.0% (pembrolizumab alone)
• 38% reduction in risk of distant metastasis or death (HR, 0.62; P = .002)
• 2-year DMFS: 88.5% vs. 80.2%
• Grade 3+ treatment-related adverse events: 14.2% vs. 13.4%

Why it matters: This trial sets a new benchmark for adjuvant melanoma treatment and validates the broader concept of individualized neoantigen-based immunotherapy. Experts are already eyeing its potential in other cancers — including lung, renal cell, and bladder — though questions around manufacturing scale, cost, and access remain key challenges ahead.